成人晚期急性淋巴细胞白血病CD19靶向免疫治疗的选择
本文讨论复发/难治性B细胞急性淋巴细胞白血病成人患者中,如何选择blinatumomab或CD19 CAR T细胞治疗,基于两种疗法的优势、局限和挑战,并考虑CD19丢失后无法接受替代CD19靶向治疗的情况。
要点
- blinatumomab和CD19 CAR T细胞均获FDA批准用于r/r ALL,后者限≤25岁。
- 选择CD19靶向治疗前需权衡各疗法优势与局限,CD19丢失者无法接受替代CD19靶向治疗。
- 两种疗法可序贯使用,但需个体化排序。
核心结论
- 在r/r B-ALL成人中,选择blinatumomab或CD19 CAR T细胞需个体化权衡,CD19丢失者将被排除于替代CD19靶向治疗之外。
研究设计与样本
- 本文为基于真实临床场景的论述,讨论r/r ALL成人选择blinatumomab或CD19 CAR T细胞治疗的理由。
主要发现
- CD19靶向免疫治疗显著改善r/r B-ALL患者结局,blinatumomab和CD19 CAR T细胞均产生高缓解率并可桥接根治性巩固治疗。
- blinatumomab和CD19 CAR T细胞均获FDA批准用于r/r ALL,CD19 CAR T细胞批准限于≤25岁患者。
- 部分接受CD19靶向免疫治疗的患者会丢失CD19表达,从而被排除于接受替代CD19靶向治疗。
关键数值与推荐
- CD19 CAR T细胞FDA批准限于年龄≤25岁的r/r ALL患者。
临床怎么用
- 临床医生应基于每位患者的个体情况,权衡blinatumomab与CD19 CAR T细胞的优势、局限和挑战后选择CD19靶向免疫治疗。
- 对于未能应答或后续复发的患者,可序贯接受blinatumomab和CD19 CAR T细胞治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-targeted immunotherapies have drastically improved outcomes for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) patients. Such therapies, including blinatumomab and CD19 chimeric antigen receptor (CD19CAR) T cells, yield high remission rates and can bridge to more definitive consolidation therapy with curative intent. Both treatments are approved by the US Food and Drug Administration (FDA) for r/r ALL (CD19CAR T-cell approval is restricted to patients ≤25 years old). Although availability of blinatumomab and CD19CAR T cells has extended options for the treatment of r/r ALL, prioritizing the sequence of these agents on an individual-patient basis may be difficult for the treating physician. Considering each therapy's advantages, limitations, and challenges is necessary when choosing between them. Although patients may receive both blinatumomab and CD19CAR T cells sequentially in cases that fail to respond or subsequently relapse, a proportion of patients treated with CD19-targeted immunotherapy will lose expression of CD19 and will be excluded from receiving the alternative CD19-targeted therapy. Thus, weighing all considerations for each patient before selecting a CD19-targeted immunotherapy is crucial. Here, we discuss real-life scenarios of adults with r/r ALL, in which we selected either blinatumomab or CD19CAR T-cell therapy, and the rationale behind each decision.
引用
- Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020. PMID: 31899793. doi:10.1182/blood.2019002132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。